Front. Pharmacol.
Frontiers in Pharmacology
Front. Pharmacol.
1663-9812
Frontiers Media S.A.
1735585
10.3389/fphar.2025.1735585
Correction
Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma
Zhu et al.
10.3389/fphar.2025.1735585
Zhu
Yan
1
†
Methodology
Writing – original draft
Conceptualization
He
Cheng
1
†
Writing – original draft
Methodology
Data curation
Cao
Shi-Chao
1
Formal analysis
Writing – review & editing
Li
Hui-Jun
2
Writing – review & editing
Investigation
Cai
Ru-Xue
3
Writing – review & editing
Conceptualization
Bai
Zhao-Jun
4
Formal analysis
Writing – review & editing
Xia
Tong-Xia
1
5
*
Writing – review & editing
Methodology
Visualization
1
Department of Pharmacy, Affiliated Hospital of Zunyi Medical University , Zunyi , Guizhou , China
2
Department of Pharmacy, Zunyi Bozhou District People’s Hospital , Zunyi , Guizhou , China
3
Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Economic and Technological Development District , Guiyang , Guizhou , China
4
Guangxi Shenli Pharmaceutical Co., Ltd. , Yulin , Guangxi , China
5
School of Nursing, Zunyi Medical University , Zunyi , Guizhou , China
* Correspondence: Tong-Xia Xia, xtx0925@163.com
†
These authors have contributed equally to this work and share first authorship
13
11
2025
2025
16
1735585
30
10
2025
31
10
2025
Copyright © 2025 Zhu, He, Cao, Li, Cai, Bai and Xia.
2025
Zhu, He, Cao, Li, Cai, Bai and Xia
https://creativecommons.org/licenses/by/4.0/
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Correction on Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma by Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025). Front. Pharmacol. 16:1556304. doi: 10.3389/fphar.2025.1556304
cost-effectiveness analysis
advanced hepatocellular carcinoma
cabozantinib
atezolizumab
sorafenib
section-in-acceptance
Drugs Outcomes Research and Policies
Affiliation 1 Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China was omitted for author Tong-Xia Xia. This affiliation has now been added for author Tong-Xia Xia.
The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Approved by: Frontiers Editorial Office , Frontiers Media SA, Switzerland